VC/PE

Francesco De Rubertis, co-founder and partner at Medicxi (left) and Graziano Seghezzi, managing partner at Sofinnova Partners (right).

Sofinnova and Medicxi talk M&A, patent cliffs, and China Sofinnova and Medicxi talk M&A, patent cliffs, and China

While we are only in the first two months of the year, Sofinnova and Medicxi spoke to us candidly about investment trends, landscapes, and how investment activity remains integral to the biotech space.

byMillie Nelson, Editor

Feb 17, 2025

|

1 Min Read

funding round on wooden blocks with dollars behind

The CAR-T promise: Umoja bags $100m in Series C financing The CAR-T promise: Umoja bags $100m in Series C financing

byMillie Nelson

Jan 28, 2025

1 Min Read

Two cartoons pushing puzzle pieces together

Chroma Medicine and Nvelop Tx merge to launch nChroma Bio with $75m Chroma Medicine and Nvelop Tx merge to launch nChroma Bio with $75m

byMillie Nelson

Dec 23, 2024

1 Min Read

Obesity on a board

Antag bags $84M in series A funding to drive obesity candidate to the clinic Antag bags $84M in series A funding to drive obesity candidate to the clinic

byMillie Nelson

Dec 19, 2024

1 Min Read

Megadeals continued amid sluggish investments and M&A in 2024 Megadeals continued amid sluggish investments and M&A in 2024

byJonathan Smith

Dec 18, 2024

1 Min Read

China on a clock

A growing phenomenon: The rise of biopharma NewCos in China A growing phenomenon: The rise of biopharma NewCos in China

byRichard Daverman

Dec 13, 2024

1 Min Read

plan prepare perform

‘Luck only comes to the most prepared people,’ says AltruBio CEO

‘Luck only comes to the most prepared people,’ says AltruBio CEO

byMillie Nelson, Editor

Money

Eyes on Asia: GSK’s $300m lupus bet, Pfizer’s $1bn China blast

Eyes on Asia: GSK’s $300m lupus bet, Pfizer’s $1bn China blast

byRichard Daverman, Editor

Panelists Anta Gkelou Partner, Sofinnova Partners; Bobby Soni CIO, BioInnovation Institute; Renee Lucander CEO, Calliditas Therapeutics

Successful mentorship between investors and CEOs hangs on respect

Successful mentorship between investors and CEOs hangs on respect

byLisa Henderson

Europe’s aversity to risk is why the US is ahead, say experts

Europe’s aversity to risk is why the US is ahead

byMillie Nelson, Editor

Money

Eyes on Asia: VC hits China, BioStar IPO, and Legend splits from GenScript

Eyes on Asia: VC hits China, BioStar IPO, and Legend splits from GenScript

byRichard Daverman, Editor

Picture with women's health written on a card in pink

Call for specific female health funding to tackle biotech finance gender gap

Call for specific female health funding to tackle biotech finance gender gap

byMillie Nelson, Editor

What’s your secret sauce? VC’s on what makes a compelling pitch

VC’s on what makes a compelling pitch

byMillie Nelson, Editor

'Is the worst behind us?' Financial expert talks biotech funding

'Is the worst behind us?' Financial expert talks biotech funding

byBrian Scanlan, Dan Stanton

Eyes on Asia: News from Sanofi, Bayer, AZ plus the return of VC?

News from Sanofi, Bayer, AZ plus the return of VC?

byRichard Daverman, Editor

Overhead view of business people working and funding

$325 million Series C funding in its Arsenal (Biosciences)

$325 million Series C funding in its Arsenal (Biosciences)

byMillie Nelson, Editor

Plenary at BIO-Europe in Munich

How industry trends are evolving biotech innovation in 2023

2023 industry trends that helped evolve biotech innovation

Eyes on Asia: Eisai $1.5bn pact, OcuMension & Alcon, TYK IPO and more

Eyes on Asia: Eisai $1.5bn pact, OcuMension & Alcon, TYK IPO and more

byRichard Daverman, Editor

GSK, Novartis, Calliditas among winners at LSX Awards

GSK, Novartis, Calliditas among winners at LSX Awards

byMillie Nelson, Editor

Subscribe to Our Newsletters

Stay updated and receive your insights for life sciences investment, innovation and partnering directly in your inbox.